Organ-specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study.

Jaekyung CheonSang-Hoon JungJung Sun KimBeodeul KangHyeyoung KimLandon L ChanLars BeckerVincent E GaillardStephen L ChanChan KimHong Jae Chon

Published in: Liver international : official journal of the International Association for the Study of the Liver (2024)

Unlike anti-PD-1 monotherapy, atezolizumab/bevacizumab demonstrated favourable responses in intrahepatic lesions, comparable to those in extrahepatic lesions, and may potentially overcome the immune-tolerant hepatic microenvironment in patients with advanced HCC.

Keyphrases

metastatic colorectal cancer
stem cells
clinical trial
study protocol
combination therapy
randomized controlled trial
double blind